WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 24, 466-488. Review Article ISSN 2277–7105

THE ROLE OF PHARMACOVIGILENCE IN PREVENTING ADVERSE DRUG REACTION: METHODS AND TECHNIQUES FOR EARLY DETECTION OF DRUG SAFETY ISSUES

[1]*Jyothsna Kommula, [2]Dr. A. Prameela Rani, [3]Sadapu Yamini, [4]Sakila Chandrika, [5]Kanaparthy Meghana

[1]Acharya Nagarjuna University, Nagarjuna Nagar, Numbur, Guntur, Andhra Pradesh, India.

Article Received on
31 October 2024,

Revised on 20 Nov. 2024,
Accepted on 10 Dec. 2024

DOI: 10.20959/wjpr202424-34946

***Corresponding Author**
Jyothsna Kommula
Acharya Nagarjuna University, Nagarjuna Nagar, Numbur, Guntur, Andhra Pradesh, India.

ABSTRACT

As the global pharmaceutical business has grown, so too has the complexity of medicine therapy, making strong pharmacovigilance (PV) systems necessary to guarantee drug safety and effectiveness. The many goals of pharmacovigilance are examined in this article, with a focus on how important it is for tracking adverse drug reactions improving risk management, and encouraging international cooperation. It emphasises how crucial it is to guarantee medication safety for a range of demographics, to identify adverse drug reactions (ADRs) and drug-drug interactions early, and modify PV systems to accommodate novel drug classes and emerging therapies. The difficulties in pharmacovigilance, such as the underreporting of adverse drug reactions, problems with data quality and the requirement for efficient causality assessment are also covered in the paper. By looking at the pharmacovigilance methods used, including patient reporting systems, spontaneous reporting systems and sophisticated statistical methods and safety. The importance, advantages, difficulties and prospects of patient reporting systems and PROs in pharmacovigilance are examined in this article. Adverse drug reactions and other drug-related problems can be reported directly to pharmaceutical companies, healthcare organizations.

KEYWORDS: Adverse drug reactions (ADR), Aims of pharmacovilance, Drug safety monitoring (DSM), challenges of adverse drug reactions, Spontaneous reporting system.

INTRODUCTION

Complexity of medication therapy rises with the growth of the global pharmaceutical business making strong pharmacovigilance systems increasingly necessary.[1] In addition to guaranteeing the effectiveness and safety of pharmaceuticals, PV aims to safeguard the general public's health by reducing the hazards connected with pharmaceuticals.[2] Strong pharmacovigilance systems must be established in both developed and developing countries to protect patients and uphold public confidence in medications.[3] Nevertheless, these systems have a number of difficulties, especially given globalization and the quick advances in medication Monitoring the long-term effects of medications detecting previously unidentified safety concerns and ensuring that regulatory bodies can take the necessary action when needed are all made possible by pharmacovigilance. Which is the detection, evaluation, comprehension and prevention of adverse drug reactions and other drug-related issues.[4] Since pharmaceutical goods are now utilized by a wide range of populations with different health conditions, genetic origins and environmental exposures, globalization has made pharmacovigilance systems' problems worse in recent years.[5]

AIMS of pharmacovigilance

A vital part of the healthcare system, pharmacovigilance (PV) seeks to guarantee the safety and functionality of medications by identifying, evaluating, comprehending and preventing adverse drug reactions and drug-related issues.[6] Pharmacovigilance (PV) systems must adjust to ever more complex and dynamic issues as the global healthcare landscape changes. The scope and goals of pharmacovigilance today are shaped by number of factors, including the emergence of new drug classes, the spread of personalized medications, the widening gaps in healthcare around the world and developing technology.[7] The many objectives of pharmacovigilance systems will be examined in this essay with an emphasis on how they take advantage of possibilities and tackle global issues to protect public health.[8]

A. Ensuring drug safety across population

Monitoring medication safety across a range of demographics and detecting and reducing any dangers related to pharmaceutical items are two of pharmacovigilance's main objectives. While many low middle income countries (LMICs) have significant gaps in reported and monitoring, affluent countries have sophisticated monitoring systems in place to track adverse medication occurrences.[9] This gap in pharmacovigilance capacity underlines the significance of ensuring that medication safety is a global endeavour not isolated to select

regions.[10] In a society where health disparities persist, this is especially difficult to ensure drug safety in diverse populations. Individuals' responses to medications may be influenced by regional differences in healthcare practices, environmental exposures and genetic profiles.[11]

B. Early detection of Adverse Drug Reactions and drug-drug interaction

Early detection of potentially adverse drug reactions and drug-drug interactions (DDIs) is the goal of pharmacovigilance systems. Due of the substantial morbidity and mortality they cause, ADRs are a persistent worldwide problem.[12] To lessen their effects ADRs must be identified early, especially when new medications are released into the market.[13] Because ADRs that were not noticed during clinical trials may surface once the medication is extensively used by a variety of demographics, the post-market surveillance phase is particularly crucial.[14] In order to discover adverse drug reactions (ADRs) that were missed in clinical trials more quickly, modern pharmacovigilance systems seek to augment pre-marketing data with real-world evidence.[15]

C. Improving risk management and risk communication

The main objectives of pharmacovigilance is risk management, which encompasses both proactive measures to stop adverse medication events and reactive measures to lessen hazards after they are discovered.[16] Pharmacovigilance systems are essential in ensuring that appropriate risk mitigation steps are implemented when safety concerns are discovered. Changing dose guidelines, adding warnings or contraindications, changing labelling or even taking a product off the market are a few examples.[17]

Risk communication, which includes information of patients, healthcare and drug safety is equally significant.[18] Good risk communication guarantees that medical personnel are aware of possible hazards and are able to prescribe drugs with knowledge.[19]

D. Promoting global collaboration and data sharing

Encouraging International Cooperation and Information Exchange Pharmacovigilance systems are increasingly focused on promoting international collaboration and sharing data on medication safety, gives the global pharmaceutical sector. The world organization initiated programme for international drug monitoring to support the gathering analysis and exchange of ADR data from various nations in an effort to advance the safe use of medications globally.[20] This cooperation is essential for identifying safety indicators that may not be

visible in different nations because of variations in prescribing procedures, health systems, and demographics.[21]

PV's data-sharing feature can improve the identification of adverse responses, particularly for medications that are used globally.[22]

E. Adapting to Emerging Therapies and New Drug Classes

Pharmacovigilance systems must constantly change to keep an eye on novel and developing treatments, especially as gene therapies, biologics and customized medications become more widely used. Because of their intricacy, innovative methods of action and application in certain patient populations, these medicines frequently pose special safety challenges.[23] For instance compared to conventional small-molecule medications, biologics and biosimilars which are derived from live organisms frequently have more intricate and unpredictable side effects.[24] Real-time monitoring and risk assessment of these novel treatments must be possible with pharmacovigilance systems.[25] Because adverse outcomes might vary among genetically diverse individuals, the introduction of targeted medicines that target certain genetic profiles also presents new issues for Pharmacovigilance systems.[26]

F. Forestering Public Awareness and Patient Engagement

Promoting Patient Involvement and Public Awareness Last but not least, pharmacovigilance programs seek to raise public awareness and adverse drug effects. Since patients who encounter adverse drug reactions are frequently the first to recognize and report them, patient and public involvement is an essential component of contemporary pharmacovigilance.[27] In addition to improving patient safety, encouraging patients to report adverse events advances the larger objective of tracking medication safety across demographics. Promoting patient involvement in pharmacovigilance requires the use of user-friendly reporting platforms, educational initiatives and public awareness campaigns.[28]

Materials and methods of Pharmacovigilance

The study of pharmacovigilance (PV) focuses on identifying, evaluating, comprehending, preventing adverse drug reactions and other drug-related issues. Strong methodology and availability of trustworthy data sources are essential for pharmacovigilance systems to function effectively.[29] Comprehensive systems and methodologies are used to collect, assess and respond to ADR data in order to monitor the functionality of medications.[30] The resources and techniques used in pharmacovigilance are covered in this section together with

information on the instruments data gathering systems, signal detection techniques and legal frameworks that guarantee medication safety.[31]

A. Techniques for Gathering Data

Data collection is the foundation of any pharmacovigilance system. Information of adverse drug reactions and other drug-related issues are gathered from different data sources to evaluate for safety of medications. Evaluating the safety profile of medications requires accurate and timely reporting of adverse drug reactions.[32]

Unplanned Report Mechanisms

The vital field of pharmacovigilance (PV) is focused on identifying, assessing, comprehending and averting adverse drug reactions and other drug-related problems.[33] Pharmacovigilance procedures are dominated by planned and methodical data collection methods but unplanned reporting mechanisms are essential for identifying drug safety problems that could otherwise go undetected.[34] These mechanisms, which frequently emerge naturally or outside of official monitoring systems, involve inadvertent or informal methods of gathering data regarding ADRs. This article explores the importance, advantages, difficulties and instances of the many unplanned reporting channels in pharmacovigilance.[35] The term "unplanned reporting mechanisms" describes the unplanned or impromptu gathering of safety data via unusual means or situations. Unplanned mechanisms arise from casual contacts, internet platforms or unforeseen discoveries in contrast to structured systems like spontaneous reporting systems or post-marketing clinical studies. These mechanisms frequently serve as the initial indicators of possible safety concerns and are useful for detecting uncommon delayed, or previously undetected ADRs.[36]

Health databases and electronic health records (EHRs)

Pharmacovigilance is using EHRs more and more to gather information on adverse drug reactions. Prescription drug information, lab findings, diagnoses and recorded adverse drug reactions are all included in these records.[37] Healthcare professionals can instantly spot any safety issues by incorporating ADR data into EHR systems.[38] Pharmacovigilance can also benefit from the use of national health surveys, hospital registries and databases of health insurance claims. Drug safety trends can be seen in these extensive databases, particularly with regard to long-term drug usage and adverse events in a variety of patient populations.[39] Health databases are structured sets of clinical and medical information, such as test findings, prescription histories, diagnostic records, patient demographics and health outcomes. These

datasets could come from research studies, registries, insurance claims or hospital.[40] EHRs are electronic health records that are kept up to date by medical professionals. They include extensive information such as imaging reports, medications, laboratory results, medical histories and treatment plans.[41] EHRs are incorporated into clinical workflows as opposed to isolated health databases, allowing for constant updates while patients are being treated.[42]

Patient Reporting Systems and Patient-Reported Outcomes (PROs)

The study and practice of monitoring and safety of medicines it involves collecting and analysing data on the effect of medicines, identifying and evaluating, comprehending, averting adverse drug reactions and taking action to reduce risks and increase benefits.[43] Pharmacovigilance has always monitored drug safety through formal reporting mechanisms and medical experts. However, patient reporting systems (PRS) and patient-reported outcomes (PROs) have become more significant in pharmacovigilance as people are increasingly acknowledged as important sources of information on their own health and pharmaceutical experiences.[44] By enabling patients to directly report adverse events, side effects and changes in their quality of life brought on by their medications, these systems offer a more comprehensive and practical understanding of drug or regulatory bodies by patients, caregivers or family members using a patient reporting system (PRS).[45] Since these systems record the viewpoints and experiences of the people who take the drugs, they differ from reporting systems that are led by medical professionals. Any health outcome that is directly reported by the patient without any interpretation by a clinical or other third party is referred to as a patient reported outcome (PRO).[46] PROs cover a variety of health-related aspects that the patient experiences, such as symptoms, side effects, functionality and quality of life (QOL).[47] PROs in pharmacovigilance offer vital insights on how patients view their care, bringing to light concerns such medication efficacy, tolerability and any side effects that might not be noticed during clinical trials or standard clinical procedures.[48]

Clinical Research and After-Market Monitoring

From clinical development to broad use in the general population, pharmacovigilance (PV) is essential to guarantee the safety and functionality of pharmacological drugs.[49] After market monitoring also known as post-market surveillance or Phase IV clinical trials is just as crucial for detecting and managing adverse drug reactions and other safety issues that might be picked up in pre-market studies as clinical research is for assessing the safety and effectiveness of medications in controlled settings.[51] The importance, difficulties and

contributions to drug safety of clinical research and post-market monitoring in pharmacovigilance are examined in this article. The foundation of drug development is clinical research, which aims to ascertain the new pharmaceutical product's safety, effectiveness, and best use.[51] This study is often undertaken in steps, beginning with preclinical investigations and going through human trials. Clinical research, which is mainly conducted in the early phases of a drug's lifecycle is essential to pharmacovigilance because it helps discover potential adverse drug reactions (ADRs) and evaluate risk profiles in a controlled setting.[52]

B. Signal detection and analysis

One of the main tasks of pharmacovigilance is signal detection, which entails examining the ADR data to find possible safety issues. Signals that can point to an underreported or undetected ADR are found using a variety of statistical techniques and algorithms. Finding trends in ADR reports that point to relationship between the medication adverse effect is the aim of signal detection.[53]

A. Spontaneous Reporting System Analysis

One of the most popular techniques for identifying adverse drug reactions (ADRs) and keeping an eye on the safety of pharmaceutical products use of spontaneous reporting systems.[54] These systems depend on individuals, healthcare providers and occasionally manufacturers to voluntarily report any suspected drug-related adverse effects. The reports produced by these impromptu submissions offer useful information that aids in the evaluation of drug safety under actual circumstances by regulatory bodies, pharmaceutical firms and medical practitioners.[55] This article explores the importance of spontaneous reporting systems (SRS) in pharmacovigilance, the methods for evaluating the information gathered and the difficulties and solutions employed to raise the system's calibre and usefulness.[56] Pharmacovigilance uses a Spontaneous Reporting System (SRS), a passive surveillance technique to gather information on adverse drug reactions (ADRs).[57] Spontaneous reporting depends on voluntary submissions from patients, healthcare providers or medication manufacturers, as opposed to active monitoring, which involves contacting patients or healthcare providers on a regular basis to report adverse drug reactions.[58] Numerous platforms, such as specialized web portals, mobile applications or conventional reporting forms can be used to submit the reports.[59] These methods are essential for finding novel, uncommon or unidentified adverse drug reactions (ADRs) that might not have been found in

clinical trials.[60] The data is sometimes seen as an early signal or indicator of a possible safety risk that may necessitate more examination because of the spontaneous nature of the reporting.[62]

Reporting Odds Ratio (ROR)

The identifying and evaluation of adverse drug reactions are essential elements of pharmacovigilance, which guarantees the security of pharmaceutical goods.[62] Effective approaches are required to estimate the risk of adverse effects, especially when new signals or safety concerns appear, because these reactions are often rare and can be impacted by a variety of circumstances.[63] The Reporting Odds Ratio (ROR) is one statistical method that is used to evaluate the degree of correlation between the medications of an adverse effect. In spontaneous reporting systems (SRS), this ratio is used to quantify the degree of correlation between a particular adverse event and a medication.[64] A statistical metric used in pharmacovigilance to assess the degree of correlation between a medication and an adverse event is the Reporting Odds Ratio (ROR). In particular, it measures the likelihood that a drug-specific adverse event will be reported in relation to the likelihood that the same adverse event would be recorded for other medications in the same system like a spontaneous reporting database.[65] In terms of mathematics, the ROR contrasts the likelihood that a particular drug will cause an adverse event with the likelihood that the same event will occur with other medications. It is mostly utilized in spontaneous reporting systems (SRS), in which patients, healthcare providers and pharmaceutical manufacturers voluntarily report adverse drug reactions (ADRs).[66]

Proportional reporting ration (PRR): A crucial component of medication safety is pharmacovigilance, which aims to track, evaluate and reduce hazards related to pharmaceutical goods after they are put on the market.[67] Analysing and recognizing adverse drug reactions (ADRs) that happen after a medicine is put on the market is the most important aspects of pharmacovigilance. Spontaneous reporting systems (SRS), which offer useful real-world data on medication safety are a key component of ADR detection.[68] One of the most popular statistical metrics in these systems for determining the probability of a given adverse event with a certain medication is the Proportional Reporting Ratio (PRR).[69] Pharmacovigilance specialists can detect warning signs of possible safety hazards by computing the PRR, which enables them to take the appropriate steps to safeguard the public's health In pharmacovigilance the Proportional Reporting Ratio (PRR) is a statistical

metric that compares the total number of adverse events reported in a spontaneous reporting system (SRS) to the probability that a given adverse event is linked to a specific medication.[70] In essence, PRR assists in determining whether an adverse event with a particular medication happens more frequently than would be predicted from the distribution of all other adverse events recorded in the system.[71] In the PRR, the percentage of cases where a certain adverse event happens with a certain drug (the numerator) is compared to the percentage of cases where the same adverse events.[72]

Bayesian Confidence Propagation Neural Network (BCPNN)

For pharmaceutical goods to be safe and effective, pharmacovigilance is essential. Due to variations in patient demographics, comorbidities and actual use, new medications frequently produce adverse reactions or side effects that were not noticed during clinical studies[73] The FDA, WHO and other regulatory agencies employ spontaneous reporting systems (SRS) to gather information about adverse drug reactions from patients, healthcare professionals and pharmaceutical firms.[74] The enormous amount of data gathered by these systems necessitates effective techniques to find possible safety signals or clues that a certain medication might be connected to a certain adverse event.[75] In pharmacovigilance Bayesian Confidence Propagation Neural Network (BCPNN) is one such technique. The Bayesian Confidence Propagation Neural Network (BCPNN) is a machine learning model that evaluates the association between medications and adverse effects by combining Bayesian statistics with a neural network architecture.[76] The BCPNN is specifically made to identify signals in pharmacovigilance data, namely any correlations between a medication and an adverse effect that would be a call for additional research. The approach is predicated on the idea of probabilistic reasoning, which updates a hypothesis regarding the likelihood of a drug-related adverse event by taking data uncertainty into account. The BCPNN method models the connections among the several pharmacovigilance entities (drugs, adverse events and patient attributes) as a probabilistic network.[77]

B. Signal Prioritization

The crucial area of medication safety known as pharmacovigilance is concerned with detecting, evaluating and averting adverse drug reactions (ADRs) as well as making sure that pharmaceutical goods are used safely.[78] As part of pharmacovigilance operations, signal detection plays a significant role in finding new, previously undiscovered dangers linked with medications after they are in the market.[79] However, given the enormous number of adverse

event reports produced by spontaneous reporting systems (SRS), it is imperative to have efficient techniques for signal prioritization, which is the process of determining which safety signals, given time and resource constraints, should be looked at first.[80] Pharmacovigilance teams can concentrate on the most significant and probable dangers by using signal prioritization, which guarantees prompt measures to safeguard the public's Signal detection is a process of recognizing a possible link between a medication and an adverse effect by statistically analysing data from clinical trials, spontaneous reporting systems or other post-marketing surveillance sources.[81] Prioritizing which signals to look into further is crucial once a signal has been recognized. The process of assessing the significance or urgency of these signals is known as signal prioritization and it helps pharmaceutical companies, healthcare practitioners and regulatory agencies decide which adverse events need the most urgent attention.[82] Pharmacovigilance resources are effectively distributed to address the most alarming safety concerns, such as serious adverse drug reactions or those that could have broad public health ramifications, thanks to signal prioritization. Setting safety signals as a top priority enables quicker regulatory responses and more efficient post-market surveillance.[83]

C. Causality Assessment

Establishing a connection between the assumed drug and the ADR is a goal of causality evaluation. This procedure makes use of a number of techniques and resources, such as the Naranjo algorithm and The World Health Organization's (WHO) Causality assessment of criteria.[84]

a. WHO Causality Assessment

A framework for determining the cause of ADRs based on available data and clinical judgment is provided by the WHO's pharmacovigilance recommendations. The evaluation takes into account elements like.

Temporal relationship: If the adverse drug reaction happened soon after the medication was given. Dechallenge and Rechallenge Whether the adverse drug reaction (ADR) improved after stopping the medication and returned after it was reintroduced.

Known drug effects: If the adverse drug reaction (ADR) is an unintended or anticipated side effect of the medication. The ADR is categorized as "certain" "probable" "possible" "unlikely or "unclassifiable" based on these standards.[85]

b. The Algorithm of Naranjo

Dr. Naranjo and associates created the Naranjo Adverse Drug Reaction Probability Scale in 1981 as a standardized instrument to determine the likelihood that a certain medication was the reason for an adverse drug reaction.[86] This scale assigns a score that represents the probability of a causal association between a medication and an adverse event using a series of structured questions based on existing clinical evidence.[87] Classifying the causality as certain, plausible, possible or unlikely might be aided by the total score. Determining the aetiology of an adverse drug reaction (ADR) is a crucial challenge in pharmacovigilance.[88] Healthcare professionals and regulatory bodies must determine whether a medicine's side effects were caused by the drug itself or by other circumstances when patients encounter them after taking it. The Naranjo Adverse Drug Reaction Probability Scale also referred to as the Naranjo Algorithm is a well-known technique for determining causality. Using the available clinical data this tool offers a methodical way to assess the possibility that a medication caused an adverse drug reaction.[89] Around the world, the Naranjo Algorithm is utilized to evaluate and classify the cause of ADRs. The methodology considers a number of factors, including the patient's medication history, clinical presentation, incident timing and alternative explanations for the adverse event.[90]

D. Regulatory Framework and Actions

A worldwide regulatory system that guarantees the efficacy and safety of medications governs pharmacovigilance. Implementing pharmacovigilance systems, gathering ADR reports and taking regulatory action to safeguard public health are the responsibilities of national regulatory agencies like the Medicines and Healthcare Products Regulatory Agency (MHRA), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA).[91]

a. Risk Management Plans (RMPs) and Risk Minimization: The safety of pharmaceutical goods is a primary concern in the subject of pharmacovigilance. Even though clinical studies offer valuable information about a drug's safety profile real safety issues frequently don't surface until a medication is put on the market and used by a larger and more varied patient base.[92] The use of Risk Management Plans (RMPs) is essential in addressing these safety hazards. Throughout their existence, these strategies assist in identifying, assessing, and reducing the hazards related to pharmaceutical products.[93] RMPs must include risk minimization techniques to make sure a drug's advantages outweigh its disadvantages.

Pharmaceutical firms and regulatory bodies collaborate to safeguard public health by implementing thorough risk management and mitigation strategies, guaranteeing that medications are taken in a safe manner.[94]

b. International Collaboration: A vital component of guaranteeing patient safety is pharmacovigilance, which is the science and practice of identifying, evaluating, comprehending and preventing adverse drug reactions (ADRs) and other drug-related issues. Effective pharmacovigilance necessitates international cooperation as worldwide travel and trade rise and as medications are used by a wider range of people with different healthcare requirements.[95] Drug safety cannot be completely monitored and managed by a single nation or regulatory body acting alone. In order to raise medication safety standards globally, encourage regulatory harmonization and safeguard the public's health, international pharmacovigilance cooperation facilitates the sharing of resources, knowledge and information.[96]

Monitoring of Adverse Drug Reactions (ADR's)

Pharmacovigilance, the field of study devoted to guaranteeing the efficacy and safety of pharmaceutical goods, includes the critical task of monitoring adverse drug reactions (ADRs). Patient safety depends on the identification, evaluation and prevention of adverse drug reactions (ADRs), which can range from minor side effects to serious illnesses. Pharmacovigilance systems around the world monitor adverse drug reactions (ADRs) by gathering information, identifying warning signs, evaluating risks and enacting laws to lessen harm.[97]

A. Importance of ADR monitors

In order to ensure the safety of pharmaceuticals, pharmacovigilance the science and practices pertaining to the identification, evaluation, comprehension and prevention of adverse drug reactions (ADRs) is essential.[98] Clinical trials have limitations even though they are crucial for determining a drug's efficacy and safety profile. When a medicine is put on the market a significantly wider range of people start using it. This implies that some side effects might not show up until the drug is taken by a larger population. Therefore, ADR monitoring is crucial for identifying, evaluating and reducing drug risks once they are marketed. The importance of ADR monitoring in pharmacovigilance, its techniques and its function in patient safety and its wider effects on healthcare systems are all examined in this article.[99] Early safety signal detection is one of the main purposes of ADR monitoring. An adverse

event is considered a safety signal if it happens more frequently than would be predicted in the general population and may be related to a medication. Pharmacovigilance professionals might find novel or unexpected side effects that might not have been noticed during clinical trials by keeping an eye on ADRs.[100]

B. Challenges of ADR monitoring

A vital part of patient safety is pharmacovigilance, which focuses on identifying, evaluating, comprehending, and averting adverse drug reactions (ADRs). Even with the strong procedures in place to keep an eye on adverse drug reactions (ADRs), detecting, reporting, and managing these responses can be extremely difficult. Drug safety management may be impacted by these issues since they have an effect on the completeness and accuracy of ADR data. The main issues with ADR monitoring are examined in this article, along with how they affect pharmacovigilance procedures.[101]

A. Underreporting of ADR's: The underreporting of adverse drug reactions is one of the biggest problems with ADR monitoring. It is well known that a significant percentage of adverse drug reactions (ADRs) are not reported, which compromises pharmacovigilance systems' capacity to identify possible safety indicators and reach well-informed conclusions regarding drug safety.[102]

B. Data Quality and Standardization: Pharmacovigilance is essential for keeping an eye on pharmaceuticals' safety and making sure they continue to be effective and safe over the course of their lives.[103] The quality and consistency of the data gathered during adverse drug reaction (ADR) monitoring are critical factors in pharmacovigilance systems' efficacy. To discover any safety concerns, evaluate risks, make well-informed regulatory choices and safeguard the public's health, high-quality, standardized data are crucial. It is impossible to overestimate the intricacy and difficulties involved in guaranteeing data consistency and quality in pharmacovigilance systems. The significance of data quality and standardization in pharmacovigilance is examined in this paper, along with the difficulties in preserving high-quality data and strategies for enhancing data gathering, exchange, and analysis in this crucial area.[104]

C. Causality Assessment: which establishes the link between a particular medication and an adverse drug reaction (ADR)? Understanding medication safety and making wise choices about clinical practice, patient care and regulatory actions depend on accurately determining

causality. The goal of pharmacovigilance is to determine and validate whether a certain medication or vaccination resulted in an adverse or unexpected reaction in a patient. Clinical judgment, data analysis and formal procedures are all used in this assessment. The procedure is not without difficulties, though as a variety of factors affect how accurately causality conclusions are made. This article explores the necessity of correct causation determination in guaranteeing patient safety, the methodologies employed, the difficulties encountered and the value of causality evaluation in pharmacovigilance.[105]

D. Global Variations: The science and practices of pharmacovigilance, or the identification, evaluation, comprehension, and avoidance of adverse drug reactions (ADRs), are essential to maintaining the safety of pharmaceuticals globally. Pharmacovigilance procedures, however, vary widely around the world. Varied nations and regions have rather varied approaches to the implementation and operation of pharmacovigilance systems. These discrepancies result from variances in data reporting procedures, economic conditions, cultural attitudes, legal frameworks and healthcare infrastructure. Gaining an understanding of these worldwide variations is essential to enhancing pharmacovigilance's efficacy and guaranteeing patient safety globally.[106]

E. Emerging Therapies: The science of identifying, evaluating, comprehending and averting adverse drug reactions (ADRs) or pharmacovigilance is crucial to guaranteeing the efficacy and safety of pharmaceuticals.[107] Emerging therapeutics from gene therapies and cell-based treatments to novel biologics and precision medicine are posing new opportunities and difficulties for pharmacovigilance systems as the pharmaceutical industry continues to change.[108] These novel treatments have the potential to treat illnesses that were previously untreatable but they also present special risks in terms of long-term consequences, safety and monitoring techniques. Pharmacovigilance needs to be adaptive due to the growing complexity of novel treatments. This article examines the new treatments. Pharmacovigilance the unique difficulties they pose, and the methods being developed to efficiently monitor their safety.[109]

CONCLUSION

Pharmacovigilance (PV) is essential for guaranteeing the effectiveness and safety of drugs in a variety of demographics. The complexity of drug therapy rises with the globalisation of the pharmaceutical business, calling for strong pharmacovigilance systems that can efficiently track and control drug-related hazards. Increasing risk management techniques, encouraging

global cooperation, and detecting adverse drug reactions (ADRs) and drug-drug interactions (DDIs) early are essential to increasing patient safety.

Pharmacovigilance has advanced, but there are still many obstacles to overcome, including the requirement for effective causality evaluations, data quality problems, and underreporting of adverse drug reactions. To close the gaps in reporting and monitoring, both developed and developing nations must fortify their pharmacovigilance systems. Furthermore, the quick development of novel medication classes and treatments.

REFERENCES

1. Gereffi G. The pharmaceutical industry and dependency in the third world.
2. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug safety. 2017 Oct; 40: 855-69.
3. World Health Organization. The importance of pharmacovigilance.
4. World Health Organization. WHO Global Surveillance and Monitoring System for substandard and falsified medical products. World Health Organization; 2017.
5. Valdova V, Sheckler RL. THE DARK SIDE OF PHARMA GLOBALIZATION.
6. Palatty PL, Sacheendran D, Jayachandran M. Mitigating Challenges in Pharmacovigilance.
7. Pappa D. The Knowledge Discovery Cube Framework A Reference Framework for collaborative, information-driven pharmacovigilance. University of Surrey (United Kingdom); 2018.
8. Pitts PJ, Le Louet H, Moride Y, Conti RM. 21st century pharmacovigilance: efforts, roles, and responsibilities. The Lancet Oncology. 2016 Nov 1; 17(11): e486-92.
9. Menang O, Kuemmerle A, Maigetter K, Burri C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. BMJ open. 2023 Sep 1; 13(9): e071079.
10. Pappa D. The Knowledge Discovery Cube Framework A Reference Framework for collaborative, information-driven pharmacovigilance. University of Surrey (United Kingdom); 2018.
11. Burke SP, Stratton K, Baciu A, editors. The future of drug safety: promoting and protecting the health of the public. National Academies Press; 2007 Mar 27.

12. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert opinion on drug safety. 2012 Jan 1; 11(1): 83-94.
13. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert opinion on drug safety. 2012 Jan 1; 11(1): 83-94.
14. DiMartino LD, Curtis LH, Williams RL, Abernethy DR. Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. Food & Drug LJ., 2008; 63: 891.
15. Chakraborty A, Venkatraman JV. Pharmacovigilance through phased clinical trials, post-marketing surveillance and ongoing life cycle safety. In The quintessence of basic and clinical research and scientific publishing 2023 Oct 1 (pp. 427-442). Singapore: Springer Nature Singapore.
16. Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug safety, 2017 Oct; 40: 855-69.
17. Gottlieb CD. 1 EMA Releases Guidance for PV Monitoring in Paediatrics. Pharmaceutical Medicine, 2019; 33: 63-78.
18. McCormack L, Craig Lefebvre R, Bann C, Taylor O, Rausch P. Consumer understanding, preferences, and responses to different versions of drug safety messages in the United States: a randomized controlled trial. Drug safety, 2016 Feb; 39: 171-84.
19. Lundgren RE, McMakin AH. Risk communication: A handbook for communicating environmental, safety, and health risks. John Wiley & Sons, 2018 Jul 10.
20. Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low-and middle-income countries: a review with particular focus on Africa. British journal of clinical pharmacology, 2023 Feb; 89(2): 491-509.
21. World Health Organization Maximizing Positive Synergies Collaborative Group. An assessment of interactions between global health initiatives and country health systems. The Lancet, 2009 Jun 20; 373(9681): 2137-69.
22. Palatty PL, Sacheendran D, Jayachandran M. Mitigating Challenges in Pharmacovigilance.
23. Gad SC. Drug safety evaluation. John Wiley & Sons; 2016 Nov 7.
24. Makurvet FD. Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery. 2021 Mar 1; 9: 100075.

25. Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A new era in pharmacovigilance: toward real-world data and digital monitoring. Clinical Pharmacology & Therapeutics. 2021 May; 109(5): 1197-202.
26. Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. Journal of the National Cancer Institute. 2014 Feb 1; 106(2): djt435.
27. Matos C, Weits G, van Hunsel F. The role of European patient organizations in pharmacovigilance. Drug Safety. 2019 Apr 5; 42: 547-57.
28. Pore AV, Bais SK, Kamble MM. PHARMACOVIGILANCE IN CLINICAL RESEARCH.
29. Nagumo WR. *Pharmacovigilance and adverse drug reaction reporting practices among Ghanaian healthcare professionals* (Doctoral dissertation, University of Sheffield).
30. Thürmann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug safety. 2001 Nov; 24(13): 961-8.
31. Lu Z. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives. Drug, healthcare and patient safety. 2009 Oct 15: 35-45.
32. Nagumo WR. *Pharmacovigilance and adverse drug reaction reporting practices among Ghanaian healthcare professionals* (Doctoral dissertation, University of Sheffield).
33. Palatty PL, Sacheendran D, Jayachandran M. Mitigating Challenges in Pharmacovigilance.
34. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). InData mining applications in engineering and medicine 2012 Aug 29. IntechOpen.
35. Pappa D. The Knowledge Discovery Cube Framework A Reference Framework for collaborative, information-driven pharmacovigilance. University of Surrey (United Kingdom); 2018.
36. Patton K, Borshoff DC. Adverse drug reactions. Anaesthesia. 2018 Jan; 73: 76-84.
37. Liu M, McPeek Hinz ER, Matheny ME, Denny JC, Schildcrout JS, Miller RA, Xu H. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. Journal of the American Medical Informatics Association, 2013 May 1; 20(3): 420-6.

38. Blake R. The Future of Healthcare: A Case for Online Dispute Resolution. International Journal of Online Dispute Resolution, 2023 Jan 1; 10(1).
39. Trifirò G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug safety, 2018 Feb; 41: 143-9.
40. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. Journal of clinical epidemiology, 2011 Apr 1; 64(4): 424-30.
41. Ambinder EP. Electronic health records. Journal of oncology practice, 2005 Jul; 1(2): 57.
42. De Moor G, Sundgren M, Kalra D, Schmidt A, Dugas M, Claerhout B, Karakoyun T, Ohmann C, Lastic PY, Ammour N, Kush R. Using electronic health records for clinical research: the case of the EHR4CR project. Journal of biomedical informatics, 2015 Feb 1; 53: 162-73.
43. Venkatesan K, Rajasekhar MB, Gowri MK, Mohapatra MN. An Introduction To Pharmacovigilance. AG PUBLISHING HOUSE (AGPH Books); 2022 Dec 13.
44. Dash S, Singh PA, Bajwa N, Choudhury A, Bisht P, Sharma R. Why Pharmacovigilance of Non-steroidal Anti-inflammatory Drugs is Important in India?. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 2024 Jun 1; 24(7): 731-48.
45. Fayers PM, Machin D. Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. John wiley & sons, 2013 May 23.
46. Shah AD, Quinn NJ, Chaudhry A, Sullivan R, Costello J, O'Riordan D, Hoogewerf J, Orton M, Foley L, Feger H, Williams JG. Recording problems and diagnoses in clinical care: developing guidance for healthcare professionals and system designers. BMJ health & care informatics, 2019; 26(1).
47. Gilbert A, Sebag-Montefiore D, Davidson S, Velikova G. Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecologic oncology, 2015 Mar 1; 136(3): 429-39.
48. World Health Organization. The importance of pharmacovigilance.
49. Beninger P. Pharmacovigilance: an overview. Clinical therapeutics, 2018 Dec 1; 40(12): 1991-2004.
50. Lemmens T, Gibson S. Decreasing the data deficit: improving post-market surveillance in pharmaceutical regulation. McGill Law Journal, 2014 Jun; 59(4): 943-88.

51. Spelsberg A, Prugger C, Doshi P, Ostrowski K, Witte T, Hüsgen D, Keil U. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. bmj., 2017 Feb 7; 356.
52. Beninger P. Pharmacovigilance: an overview. Clinical therapeutics, 2018 Dec 1; 40(12): 1991-2004.
53. Păcurariu A. The role of signal detection in Pharmacovigilance.
54. Al-Worafi YM. Technology for drug safety: Current status and future developments. Springer Nature, 2023 Jul 18.
55. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Archives of internal medicine, 2005 Jun 27; 165(12): 1363-9.
56. Nagumo WR. *Pharmacovigilance and adverse drug reaction reporting practices among Ghanaian healthcare professionals* (Doctoral dissertation, University of Sheffield).
57. Schurer MJ. *Towards the interoperability of spontaneous reporting systems in pharmacovigilance: A maturity model approach with a sociotechnical system focus* (Doctoral dissertation, Stellenbosch: Stellenbosch University).
58. Berniker J. Spontaneous reporting systems: Achieving less spontaneity and more reporting.
59. Hu X, Chu TH, Leung VC, Ngai EC, Kruchten P, Chan HC. A survey on mobile social networks: Applications, platforms, system architectures, and future research directions. IEEE Communications Surveys & Tutorials, 2014 Nov 20; 17(3): 1557-81.
60. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug safety, 2006 May; 29(5): 385-96.
61. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety, 2001 Oct; 10(6): 483-6.
62. Pozsgai K, Szűcs G, Kőnig-Péter A, Balázs O, Vajda P, Botz L, Vida RG. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study. Frontiers in pharmacology, 2022 Sep 6; 13: 964399.
63. Effective approaches are required to estimate the risk of adverse events, especially when new signals or safety concerns appear, because these reactions are often rare and can be impacted by a variety of circumstances.

64. van der Heijden PG, van Puijenbroek EP, van Buuren S, Van der Hofstede JW. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Statistics in medicine, 2002 Jul 30; 21(14): 2027-44.
65. Liu M, McPeek Hinz ER, Matheny ME, Denny JC, Schildcrout JS, Miller RA, Xu H. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. Journal of the American Medical Informatics Association, 2013 May 1; 20(3): 420-6.
66. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). InData mining applications in engineering and medicine 2012 Aug 29. IntechOpen.
67. World Health Organization. The importance of pharmacovigilance.
68. Montastruc JL, Sommet A, Lacroix I, Olivier P, Durrieu G, Damase-Michel C, Lapeyre-Mestre M, Bagheri H. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine, 2006 Dec 1; 73(6): 629-32.
69. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and drug safety, 2002 Jan; 11(1): 3-10.
70. Venkatesan K, Rajasekhar MB, Gowri MK, Mohapatra MN. An Introduction To Pharmacovigilance. AG PUBLISHING HOUSE (AGPH Books), 2022 Dec 13.
71. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacological reviews, 2013 Apr 1; 65(2): 779-808.
72. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety, 2001 Oct; 10(6): 483-6.
73. Li Y, Wu Y, Jiang T, Xing H, Xu J, Li C, Ni R, Zhang N, Xiang G, Li L, Li Z. Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature. Therapeutic Advances in Drug Safety, 2023 Sep; 14: 20420986231200746.
74. Srba J. Pharmacovigilance: Spontaneous reporting systems.
75. Reason J. Understanding adverse events: human factors. BMJ Quality & Safety, 1995 Jun 1; 4(2): 80-9.

76. Bansal D, Muhammed Favas KT, Yoosuf BT. 9 Bayesian Methods of Signal Detection. Signal Analysis in Pharmacovigilance: Principles and Processes, 2024 Sep 26: 135.
77. Lee CY, Chen YP. Machine learning on adverse drug reactions for pharmacovigilance. Drug discovery today, 2019 Jul 1; 24(7): 1332-43.
78. World Health Organization. The importance of pharmacovigilance.
79. Ansari H, Kisku A. Role of Social Media for Drug Safety Signal Detection.
80. Kalid N, Zaidan AA, Zaidan BB, Salman OH, Hashim M, Muzammil HJ. Based real time remote health monitoring systems: A review on patients prioritization and related" big data" using body sensors information and communication technology. Journal of medical systems, 2018 Feb; 42: 1-30.
81. Hammad TA, Davis S, Afsar S. Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence. Frontiers in Drug Safety and Regulation, 2024 Aug 16; 4: 1445998.
82. World Health Organization. The importance of pharmacovigilance.
83. Nwokike J. *Regulatory reliance and post-marketing surveillance systems for safe and accelerated introduction of new medical products in low-and middle-income countries* (Doctoral dissertation, University of Plymouth).
84. Deutscher B, Falconer N, De Guzman K, La Caze A. A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting. Expert Review of Clinical Pharmacology. 2024 Nov 15(just-accepted).
85. Schatz S, Weber RJ. Adverse drug reactions. Pharmacy Practice, 2015 Aug 24; 1(1): 16.
86. Gallagher R. *Adverse Drug Reactions Causing Admission in Children* (Doctoral dissertation, University of Liverpool).
87. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug safety, 2008 Jan; 31: 21-37.
88. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug safety, 2008 Jan; 31: 21-37.
89. Gallagher R. *Adverse Drug Reactions Causing Admission in Children* (Doctoral dissertation, University of Liverpool).
90. Kumar A, Nanda D, Gupta A. A HOLISTIC APPROACH TO ADVERSE DRUG REACTIONS IN HOSPITALS: CLASSIFICATION, RISK FACTORS, ASSESSMENT AND ECONOMIC EVALUATION-A REVIEW. Journal of Experimental Zoology India. 2024 Jul 1; 27(2).

91. Van Norman GA. Drugs and devices: comparison of European and US approval processes. JACC: Basic to Translational Science, 2016 Aug; 1(5): 399-412.
92. Burke SP, Stratton K, Baciu A, editors. The future of drug safety: promoting and protecting the health of the public. National Academies Press, 2007 Mar 27.
93. Mohiuddin AK. Medication Risk Management. INNOVATIONS in pharmacy, 2019; 10(1).
94. Seiter A. A practical approach to pharmaceutical policy. World Bank Publications; 2010 Jun 17.
95. Jose J, Cox AR, Bate A. Introduction to Drug Safety and Pharmacovigilance. InPrinciples and Practice of Pharmacovigilance and Drug Safety, 2024 Aug 6 (pp. 3-30). Cham: Springer International Publishing.
96. Raut N, Bajaj K, Matte P, Vhora M, Kale V, Umekar M, Harane S. Building Bridges: Harmonization efforts for enhanced collaboration between developed and developing countries. International Journal Of Drug Regulatory Affairs, 2023; 11(3): 68-79.
97. World Health Organization. The importance of pharmacovigilance.
98. Venkatesan K, Rajasekhar MB, Gowri MK, Mohapatra MN. An Introduction To Pharmacovigilance. AG PUBLISHING HOUSE (AGPH Books), 2022 Dec 13.
99. Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. British journal of clinical pharmacology, 2017 Feb; 83(2): 227-46.
100. Subash V. ADVERSE DRUG REACTION AND PHARMACOVIGILANCE-AN OVERVIEW.
101. Molokhia M, Tanna S, Bell D. Improving reporting of adverse drug reactions: systematic review. Clinical epidemiology, 2009 Aug 9: 75-92.
102. Njiru JW. *Determinants of adverse drug reactions reporting in retail chemists in Nairobi County, Kenya* (Doctoral dissertation, KeMU).
103. Waller P, Harrison-Woolrych M. An introduction to pharmacovigilance. John Wiley & Sons; 2017 May 1.
104. Lindquist M. Data quality management in pharmacovigilance. Drug safety, 2004 Oct; 27(12): 857-70.
105. World Health Organization. The importance of pharmacovigilance.
106. Ferlie EB, Shortell SM. Improving the quality of health care in the United Kingdom and the United States: a framework for change. The Milbank Quarterly, 2001 Jun; 79(2): 281-315.

107. Pore AV, Bais SK, Kamble MM. PHARMACOVIGILANCE IN CLINICAL RESEARCH.
108. Al-Mahayri ZN, Nagy M. Safety Pharmacology in the Era of Precision Medicine. InDrug Discovery and Evaluation: Safety and Pharmacokinetic Assays 2024 Mar 18 (pp. 1-16). Cham: Springer International Publishing.
109. O'Shaughnessy, J.A., Kelloff, G.J., Gordon, G.B., Dannenberg, A.J., Hong, W.K., Fabian, C.J., Sigman, C.C., Bertagnolli, M.M., Stratton, S.P., Lam, S. and Nelson, W.G., 2002. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development: recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia. *Clinical Cancer Research*, *8*(2): 314-346.